Multicenter Registry of Patients With Subarachnoid Hemorrhage
ConditionSubarachnoid Hemorrhage, Spontaneous
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUMC Utrecht
About this trial
The purpose of this registry is to collect detailed information on the characteristics, treatment, and outcomes of patients with a subarachnoid hemorrhage. This information will enable research aimed at improving the safety and effectiveness of current and future treatments. By studying these data, the investigators aim to identify which treatment strategies offer the best results and which factors are most important in the care of patients with a subarachnoid hemorrhage. The knowledge gained from this research will help improve patient care in the future.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Spontaneous subarachnoid hemorrhage with blood in the basal cisterns and/or major fissures on non-contrast head computed tomography (CT), or xanthochromia of cerebrospinal fluid confirmed by spectrophotometric analysis.
Aneurysmal SAH
SAH from other intracranial vascular malformation (e.g. AVM, dural AVF)
Disqualifiers
Traumatic, neoplastic, infection related (except mycotic aneurysms), or iatrogenic SAH
Isolated convexity SAH
Trial population
Patients with spontaneous subarachnoid hemorrhage
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
None, observational study
Other interventionNone, observational study
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: Spontaneous Subarachnoid Hemorrhage1 intervention
Trial outcomes
Primary outcomes
1
Modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.
Time frame
6 months ± 30 days after SAHSecondary outcomes
1
modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.
Time frame
18 months ± 30 days after SAH2
Complications related to treatment of the ruptured aneurysm
Time frame
Periprocedural3
Complications related to SAH
Time frame
During registry period (up to 18 months after SAH)4
Degree of aneurysm occlusion
For endovascular treatment assessed by the modified Raymond Roy Classification
Time frame
Up to 18 months after SAHSponsors and contacts
Click on the lead sponsor to view all of their trials.
UMC Utrecht
Lead sponsor
Dutch Heart Foundation
Collaborator
The Dutch Brain Foundation
Collaborator
Radboud University Medical Center
Collaborator
Erasmus Medical Center
Collaborator
Maastricht University Medical Center
Collaborator
Elisabeth-TweeSteden Ziekenhuis
Collaborator
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Collaborator
Isala
Collaborator
Medical Center Haaglanden
Collaborator
University Medical Center Groningen
Collaborator
Source ClinicalTrials.gov